Role of ssDNA as a Noninvasive Indicator for the Diagnosis and Prognosis of Hepatocellular Carcinoma: An Exploratory Study
Table 1
Relationship between ssDNA levels and clinical characteristics of 102 patients with HCC.
Characteristics
(%)
ssDNA levels (ng/μL), median (IQR)
All
102 (100)
23.20 (16.86-44.40)
Age (years)
≤60
33 (32.4)
21.20 (15.75-58.60)
60+
69 (67.6)
23.80 (18.05-39.84)
0.99a
Sex
Male
77 (75.5)
23.80 (17.30-51.69)
Female
25 (24.5)
21.20 (15.75-37.87)
0.42a
AFP level
AFP-negative HCC
61 (59.8)
20.20 (15.88-50.33)
ng/mL
41 (40.2)
31.50 (18.69-37.58)
0.33a
Cirrhosis
Cirrhosis-negative HCC
47 (46.1)
26.64 (16.34-52.35)
Cirrhosis-positive HCC
55 (43.9)
21.46 (18.02-40.91)
0.64a
Tumor size (mm) (sum of all tumors)
≤20
30 (29.4)
19.60 (15.20-48.60)
20-50
35 (34.3)
19.20 (15.83-47.55)
≥50
37 (36.3)
30.80 (20.07-38.39)
0.13b
Tumor stage (TNM)
I
37 (36.3)
18.93 (15.98-34.70)
II
42 (41.2)
22.63 (16.86-49.80)
III-IV
23 (22.6)
34.80 (22.25-54.58)
0.02b
Resected HCC
Yes
62 (60.8)
19.70 (15.80-37.80)
No
40 (39.2)
28.50 (19.34-54.05)
0.02a
Lymph node metastasis
Yes
13 (12.8)
48.60 (19.65-60.60)
No
89 (87.2)
21.20 (16.85-38.39)
0.09a
Distant metastasis
Yes
9 (8.8)
53.20 (25.85-96.00)
No
93 (91.2)
21.20 (16.65-39.84)
0.04a
HBV infection
HBV+
76 (74.5)
21.00 (16.49-44.40)
HBV-
26 (25.5)
32.70 (18.18-48.60)
0.36a
Note: IQR: interquartile range. aComparison between the two groups was analyzed using the Mann–Whitney test; bcomparison among the multiple groups was analyzed using the Kruskal-Wallis test.
